New‐onset psoriasis after Comirnaty (
            <scp>BNT162b2</scp>
            ,
            <scp>BioNTech</scp>
            /Pfizer) vaccine successfully treated with ixekizumab

Cortonesi, Giulio; Orsini, Corinne; Rubegni, Pietro; Trovato, Emanuele

doi:10.1111/dth.15606

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 49 studies involving 134 patients were included in this review ( Figure 1 ) and are summarized in Table 1 (new-onset psoriasis) [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ] and Table 2 (psoriasis exacerbation) [ 32 , 33 , 34 , 35 , 39 , 45 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ,…”

Section: Resultsmentioning

confidence: 99%

“…The exact triggers for new-onset psoriasis can vary among individuals, but potential factors include infections, physical trauma to the skin, stress, certain medications, and hormonal changes. As regards cases of new-onset psoriasis following COVID-19 vaccination, a total of 27 (male: 10 (37.0%); female: 13 (48.1%); not reported: 4 (14.8%); mean age: 54.4 ± 20.9 years) cases reported in 20 manuscripts are described and summarized in Table 1 [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ]. In particular, plaque psoriasis was the commonest clinical phenotype ( n = 9 (33.3%)), followed by guttate (7 (25.9%)), pustular (4 (14.8%)), nail (3 (11.1%)) and annular psoriasis (1 (3.7%)), while the clinical phenotype of the remaining 3 (11.1%) subjects has not been reported.…”

Section: Resultsmentioning

confidence: 99%

“…In total, 49 studies involving 134 patients were included in this review (Figure 1) and are summarized in Table 1 (new-onset psoriasis) [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] and Table 2 (psoriasis exacerbation) [32][33][34][35]39,45,.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

et al. 2023

View full text Add to dashboard Cite

COVID-19 vaccination was the main measure to overcome the pandemic. As with other drugs and vaccines, mild to moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions have been described. In particular, there are several reports investigating de novo psoriasis or the exacerbation of psoriasis following COVID-19 vaccination. However, data on the possible pathogenetic mechanisms as well as comprehensive manuscripts on the topic are scant. Thus, the aim of our manuscript was to perform a review of the current literature on post-COVID-19 vaccination exacerbations and new-onset psoriasis in order to offer a wide perspective on this area and to point out possible pathogenetic mechanisms. Research on the current literature was performed following PRISMA guidelines. In total, 49 studies involving 134 patients developing new-onset psoriasis (n = 27, 20.1%) or psoriasis exacerbation (n = 107, 79.9%) were collected. Although cases of de novo psoriasis or a worsening of psoriasis have been reported following vaccination, all of the cases have been successfully treated while overall benefit–risk profile of COVID-19 vaccination does not justify vaccine hesitancy due to the risk of psoriasis being developed or worsening. Certainly, further studies are needed to identify possible pathogenetic mechanisms in order to identify “at-risk” patients. Finally, vaccination should not be discouraged.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

et al. 2023

View full text Add to dashboard Cite

show abstract

“…What is increased are reports in the literature of new onsets or exacerbations of psoriasis. A distinction should be made in the case of psoriasis in that both new onsets of the condition and flare-ups of pre-existing psoriasis are reported for a total of 98 cases; 81 cases [ 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ] involved flare-ups while the remaining 17 cases involved new onsets of psoriasis [ 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ]. Several phenotypes have been described, such as erythrodermic, nail psoriasis, pustular psoriasis, but the plaque and guttate forms are definitely the most frequent [ 71 , 72 ].…”

Section: Resultsmentioning

confidence: 99%

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature

Fabbrocini

Battista

Ruggiero

et al. 2023

Viruses

View full text Add to dashboard Cite

Background: Four vaccines have been authorized by the European Medicines Agency (EMA): viral vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2. and 2 mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273). Adverse events (AEs) related to vaccination have been described in the literature. The main aim of the dermatological practice was to avoid the diffusion of COVID-19, allowing the continuity of care for patients. Objective: The aim of this review article is to investigate current literature regarding cutaneous reactions following COVID-19 vaccination, mainly inflammatory dermatological diseases. Materials and methods: Investigated manuscripts included metanalyses, reviews, letters to the editor, real-life studies, case series, and reports. Results: We selected a total of 234 articles involving more than 550 patients. We have divided the results section into various sub-sections to ensure greater understanding for readers. Conclusions: Clinicians should keep in mind the possibility of new onsets or the worsening of several dermatoses following vaccination in order to promptly recognize and treat these AEs. Certainly, vaccination should not be discouraged.

show abstract

“…Main Cutaneous Reaction Following COVID-19 Vaccination Ouni et al24 (2), Nagrani et al35 (1), Song et al46 (1), Frioui et al49 (1), Cortonesi et al50 (1), Lehmann et al51 (1), Elamin et al52 (1), Wei et al53 (1), Lamberti et al54 (1), Romagnuolo et al25 (1), Ruggiero et al26 (1), Ricardo et al27 (1), Pesqué et al28 …”

mentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

New‐onset psoriasis after Comirnaty ( BNT162b2 , BioNTech /Pfizer) vaccine successfully treated with ixekizumab

Cited by 5 publications

References 9 publications

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Contact Info

Product

Resources

About